 |
市场调查报告书
商品编码
1920866
脉络膜新生血管市场规模、份额和成长分析（按疾病类型、治疗类型、给药途径、最终用户、年龄层和地区划分）—2026-2033年产业预测Choroidal Neovascularization Market Size, Share, and Growth Analysis, By Disease Type, By Treatment Type, By Route of Administration, By End User, By Age Group, By Region - Industry Forecast 2026-2033 |
||||||
全球脉络膜新生血管市场规模预计在 2024 年达到 63 亿美元，从 2025 年的 67 亿美元成长到 2033 年的 109.2 亿美元，在预测期（2026-2033 年）内复合年增长率为 6.3%。
由于老龄化相关疾病的增加和老年人口的不断增长，脉络膜新生血管市场正经历显着增长。全球趋势表明，老龄化相关眼科疾病，尤其是可导致脉络膜新生血管的黄斑部病变，正显着增加。病例数的激增凸显了早期诊断和针对老年族群制定的有效治疗策略的必要性。先进的影像技术和治疗方法创新显着改善了临床疗效，并提升了视网膜疾病的整体医疗应对能力。此外，促进医疗服务的公平获取和患者的积极参与也推动了市场扩张。然而，高昂的治疗费用和有限的医疗服务取得等挑战，需要持续的创新和投资，以改善医疗服务，提高受影响人口的医疗可近性。
全球脉络膜新生血管市场驱动因素
全球脉络膜新生血管市场的主要驱动因素之一是老龄化黄斑部病变(AMD) 和其他视网膜疾病盛行率的上升。随着人口老化，AMD（通常会导致脉络膜新生血管形成）的发生率正在迅速增加，因此亟需更先进的治疗方案。不断扩大的患者群体推动了对新型治疗方法和技术的需求，包括抗 VEGF 注射和雷射治疗。此外，人们对眼部健康的日益重视以及诊断技术的进步使得早期发现和早期疗育成为可能，进一步促进了市场成长。因此，製药公司正积极投资研发，以满足该领域尚未满足的需求。
限制全球脉络膜新生血管市场的因素
全球脉络膜新生血管市场的主要限制因素之一是先进治疗方法方法的高成本。许多用于治疗该疾病的创新方案，例如抗VEGF注射和雷射治疗，往往价格昂贵，且并非所有保险公司都承保。这种经济障碍可能会限制患者获得必要的治疗，并阻碍市场整体成长。此外，不同地区在治疗核准和报销政策方面的监管和政策差异，也增加了製造商和医疗服务提供者的复杂性，可能减缓新技术的应用，并限制市场扩张。
全球脉络膜新生血管市场趋势
全球脉络膜新生血管市场正经历深刻的变革时期，这主要得益于抗血管内皮生长因子（VEGF）疗法的进步。长效製剂和高效给药系统等创新正在改变治疗模式，减少患者就诊次数，提升治疗便利性。这种变革不仅改善了治疗效果，也提高了患者满意度，而患者满意度对于持续治疗至关重要。这些趋势反映了生物製药研发的持续进展，凸显了市场的动态特性：新兴治疗方法和技术进步不断重塑市场竞争格局，最终改善脉络膜新生血管的患者照护照护水准。
目录
介绍
- 调查目标
- 市场定义和范围
调查方法
- 调查过程
- 二手资料和一手资料方法
- 市场规模估算方法
执行摘要
- 全球市场展望
- 市场主要亮点
- 细分市场概览
- 竞争格局概述
市场动态与展望
- 总体经济指标
- 驱动因素和机会
- 限制与挑战
- 供给面趋势
- 需求面趋势
- 波特的分析和影响
关键市场考察
- 关键成功因素
- 影响市场的因素
- 关键投资机会
- 生态系测绘
- 市场吸引力指数（2025）
- PESTEL 分析
- 价值链分析
- 定价分析
- 案例研究
- 监管环境
- 技术评估
- 技术评估
- 监管环境
全球脉络膜新生血管市场规模（按疾病类型和复合年增长率划分）（2026-2033 年）
- 老龄化黄斑部病变
- 病理性近视
- 眼组织胞浆菌病
- 其他视网膜疾病
全球脉络膜新生血管市场规模（按治疗方法和复合年增长率划分）（2026-2033 年）
- 抗 VEGF 疗法
- 动态疗法
- 皮质类固醇
全球脉络膜新生血管治疗市场规模（按给药途径和复合年增长率划分）（2026-2033 年）
- 玻璃体内注射
- 口服
- 其他的
全球脉络膜新生血管市场规模（按最终用户和复合年增长率划分）（2026-2033 年）
- 医院
- 眼科诊所
- 门诊手术中心
全球脉络膜新生血管市场规模（依年龄层划分）及复合年增长率（2026-2033 年）
- 成人版
- 老年人
全球脉络膜新生血管市场规模及复合年增长率（2026-2033）
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
- 亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
- 拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地区
- 中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区
竞争资讯
- 前五大公司对比
- 主要企业的市场定位（2025 年）
- 主要市场参与者所采取的策略
- 近期市场趋势
- 公司市占率分析（2025 年）
- 主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较
主要企业简介
- Roche
- Novartis
- Bayer
- Regeneron Pharmaceuticals
- AbbVie
- Pfizer
- Santen Pharmaceutical
- Samsung Bioepis
- Amgen
- Biogen
- Kodiak Sciences
- Outlook Therapeutics
- Graybug Vision
- Ocular Therapeutix
- Bausch+Lomb
- Alimera Sciences
- Apellis Pharmaceuticals
- EyePoint Pharmaceuticals
- Genentech
- Alcon
结论与建议
Global Choroidal Neovascularization Market size was valued at USD 6.3 billion in 2024 and is poised to grow from USD 6.7 billion in 2025 to USD 10.92 billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).
The choroidal neovascularization market is witnessing significant growth fueled by the increasing prevalence of age-related diseases and a rising geriatric population. With global aging trends, there is a marked rise in ocular disorders linked to aging, particularly conditions like macular degeneration that lead to choroidal neovascularization. This surge in cases emphasizes the need for early diagnosis and effective treatment strategies tailored for the elderly. Advanced imaging technologies and therapeutic innovations have markedly enhanced clinical outcomes and the overall healthcare response to retinal diseases. Additionally, the push for equitable access to care and active patient participation is propelling market expansion. However, challenges such as high treatment costs and limited healthcare access necessitate ongoing innovation and investment to improve care delivery and affordability for affected populations.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Choroidal Neovascularization market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Choroidal Neovascularization Market Segments Analysis
Global Choroidal Neovascularization Market is segmented by Disease Type, Treatment Type, Route of Administration, End User, Age Group and region. Based on Disease Type, the market is segmented into Age-related Macular Degeneration, Pathologic Myopia, Ocular Histoplasmosis and Other Retinal Disorders. Based on Treatment Type, the market is segmented into Anti-VEGF Therapy, Photodynamic Therapy and Corticosteroids. Based on Route of Administration, the market is segmented into Intravitreal Injection, Oral and Others. Based on End User, the market is segmented into Hospitals, Ophthalmology Clinics and Ambulatory Surgical Centers. Based on Age Group, the market is segmented into Adult and Geriatric. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Choroidal Neovascularization Market
One key market driver for the global choroidal neovascularization market is the rising prevalence of age-related macular degeneration (AMD) and other retinal disorders. As populations age, the incidence of AMD, which often leads to choroidal neovascularization, has surged, necessitating advanced treatment options. This growing patient base has spurred demand for novel therapies and technologies, including anti-VEGF injections and laser treatments. Additionally, increased awareness surrounding eye health and advancements in diagnostic techniques are enhancing early detection and intervention, further fueling market growth. Consequently, pharmaceutical companies are actively investing in research and development to address the unmet medical needs in this segment.
Restraints in the Global Choroidal Neovascularization Market
One key market restraint for the global choroidal neovascularization market is the high cost of advanced treatments and therapies. Many innovative solutions for managing this condition, including anti-VEGF injections and laser therapies, are often expensive and may not be covered by all insurance providers. This financial barrier can limit patient access to essential care and hinder overall market growth. Additionally, varying regulations across different regions regarding treatment approvals and reimbursement policies can add complexity for manufacturers and healthcare providers, potentially stalling the adoption of new technologies and limiting market expansion.
Market Trends of the Global Choroidal Neovascularization Market
The Global Choroidal Neovascularization market is experiencing a significant shift driven by advancements in anti-VEGF therapies. Innovations such as longer-acting formulations and more efficient delivery systems are transforming treatment practices, allowing for fewer clinic visits and enhancing patient convenience. This evolution not only improves therapeutic outcomes but also boosts patient satisfaction, which is critical for treatment adherence. As a reflection of ongoing biopharmaceutical research and development, these trends highlight the market's dynamic nature, where emerging therapies and technological advancements continuously shape the competitive landscape, ultimately leading to improved patient care and outcomes in managing choroidal neovascularization.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index, 2025
- PESTEL Analysis
- Value Chain Analysis
- Pricing Analysis
- Case Studies
- Regulatory Landscape
- Technology Assessment
- Technology Assessment
- Regulatory Landscape
Global Choroidal Neovascularization Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Age-related Macular Degeneration
- Pathologic Myopia
- Ocular Histoplasmosis
- Other Retinal Disorders
Global Choroidal Neovascularization Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Anti-VEGF Therapy
- Photodynamic Therapy
- Corticosteroids
Global Choroidal Neovascularization Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravitreal Injection
- Oral
- Others
Global Choroidal Neovascularization Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Ophthalmology Clinics
- Ambulatory Surgical Centers
Global Choroidal Neovascularization Market Size by Age Group & CAGR (2026-2033)
- Market Overview
- Adult
- Geriatric
Global Choroidal Neovascularization Market Size & CAGR (2026-2033)
- North America (Disease Type, Treatment Type, Route of Administration, End User, Age Group)
- US
- Canada
- Europe (Disease Type, Treatment Type, Route of Administration, End User, Age Group)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Disease Type, Treatment Type, Route of Administration, End User, Age Group)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Disease Type, Treatment Type, Route of Administration, End User, Age Group)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Disease Type, Treatment Type, Route of Administration, End User, Age Group)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Santen Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Bioepis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kodiak Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Outlook Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Graybug Vision
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ocular Therapeutix
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch + Lomb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alimera Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apellis Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- EyePoint Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genentech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alcon
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
